Cardiology CNE/CPE/CME Course 4 | Best Practices for Treating HCM: Global Views

Program Description

Hypertrophic cardiomyopathy (HCM) can be a chronic, progressive condition in which patients experience symptoms of dyspnea, dizziness, and fatigue as well as serious complications such as heart failure, arrhythmias, stroke, and sudden cardiac death. HCM is a masquerading disease and is easily confused with other conditions. Because there are many different symptomatic manifestations of HCM, clinicians are not always up to date with evidence-based treatment recommendations, missing opportunities to provide relief to patients with HCM. Practice guidelines for HCM released in December 2020 by the AHA/ACC provide further detail on when to use available treatment options. Clinicians need to stay current on the latest recommendations to prepare to treat or refer patients with HCM to a specialist.

Join Drs. Maron and Olivotto in this 2nd installment of a 3-part CMEO Snack series on HCM as they identify strategies for clinicians to better implement global and country-specific guideline recommendations to improve care for patients with HCM.

Educational Objectives

Upon completion, participants should be able to:

• Assess safety and efficacy of emerging agents.

Intended Audience

Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists).

Commercial Supporter

Supported by an educational grant from Bristol Myers Squibb.

Max Credits

• 0.50 / AMA PRA Category 1 Credit
• 0.50 / ABIM MOC Point
• 0.50 / AAPA Category 1 CME Credit
• 0.50 / ANCC Contact Hour
• 0.50 / CE for Pharmacists

Expires: May 10, 2023